These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study. Noguchi LM, Richardson BA, Baeten JM, Hillier SL, Balkus JE, Chirenje ZM, Bunge K, Ramjee G, Nair G, Palanee-Phillips T, Selepe P, van der Straten A, Parikh UM, Gomez K, Piper JM, Watts DH, Marrazzo JM, VOICE Study Team. Lancet HIV; 2015 Jul; 2(7):e279-87. PubMed ID: 26155597 [Abstract] [Full Text] [Related]
3. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk. Seidman D, Averbach S, Smith-McCune K, Darney P. Lancet HIV; 2015 Sep; 2(9):e365-6. PubMed ID: 26423545 [No Abstract] [Full Text] [Related]
5. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk - Authors' reply. Noguchi LM, Richardson BA, Balkus JE, Marrazzo JM. Lancet HIV; 2015 Sep; 2(9):e366-7. PubMed ID: 26423547 [No Abstract] [Full Text] [Related]
6. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk - Authors' reply. Jones HE, van de Wijgert JH. Lancet HIV; 2015 Sep; 2(9):e367. PubMed ID: 26423549 [No Abstract] [Full Text] [Related]
7. Interpretation, communication, and mechanisms of associations between injectable contraception and HIV risk. Hofmeyr GJ, Singata M, Lawrie TA, Temmerman M. Lancet HIV; 2015 Sep; 2(9):e365. PubMed ID: 26423546 [No Abstract] [Full Text] [Related]
8. Effects of injectable contraception with depot medroxyprogesterone acetate or norethisterone enanthate on estradiol levels and menstrual, psychological and behavioral measures relevant to HIV risk: The WHICH randomized trial. Singata-Madliki M, Smit J, Beksinska M, Balakrishna Y, Avenant C, Beesham I, Seocharan I, Batting J, Hapgood JP, Hofmeyr GJ. PLoS One; 2024 Sep; 19(3):e0295764. PubMed ID: 38530848 [Abstract] [Full Text] [Related]
9. Hormonal contraceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. Polis CB, Phillips SJ, Curtis KM, Westreich DJ, Steyn PS, Raymond E, Hannaford P, Turner AN. Contraception; 2014 Oct; 90(4):360-90. PubMed ID: 25183264 [Abstract] [Full Text] [Related]
10. WHO special programme of research, development and research training in human reproduction. Task force on long-acting agents for the regulation of fertility. Contraception; 1982 Jan; 25(1):1-11. PubMed ID: 6460593 [Abstract] [Full Text] [Related]
12. Hormonal contraceptive use and women's risk of HIV acquisition: priorities emerging from recent data. Ralph LJ, Gollub EL, Jones HE. Curr Opin Obstet Gynecol; 2015 Dec; 27(6):487-95. PubMed ID: 26536211 [Abstract] [Full Text] [Related]
16. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. Kleinschmidt I, Rees H, Delany S, Smith D, Dinat N, Nkala B, McIntyre JA. Contraception; 2007 Jun; 75(6):461-7. PubMed ID: 17519153 [Abstract] [Full Text] [Related]
18. Hormonal contraception and the risk of HIV acquisition among women in South Africa. Morrison CS, Skoler-Karpoff S, Kwok C, Chen PL, van de Wijgert J, Gehret-Plagianos M, Patel S, Ahmed K, Ramjee G, Friedland B, Lahteenmaki P. AIDS; 2012 Feb 20; 26(4):497-504. PubMed ID: 22156973 [Abstract] [Full Text] [Related]